![Maureen McEnroe](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Perfil
Ms. Maureen McEnroe, CFA MBA, is an Advisor at Iguana Healthcare Management LLC.
She provides independent buy-side analysis through the firm MAC Healthcare Consulting.
For the last seven years, she has worked with a variety of hedge funds and mutual funds giving long/short trading and investment ideas in the healthcare services sector.
Prior to founding MAC Healthcare Consulting, Ms. McEnroe was the Healthcare Services Portfolio Manager at Merlin BioMed Group.
She worked at Merlin BioMed from July of 1999 through December 2002.
Before moving to the buy-side, she had almost ten years of sell-side research and banking experience at Prudential, Merrill Lynch, and HCF/Brenner Securities.
She was the Director of Healthcare Research at HCF/Brenner, and a senior biotechnology and bioinstrumentation at Merrill Lynch Capital Markets from 1990 until 1995.
Prior to that, she was a Junior Biotechnology analyst at Prudential Securities.
She also had a successful nursing career at Memorial Sloan Kettering Cancer Center.
Ms. McEnroe received an MBA from the Stern School of Business at New York University in 1989 and a Nursing degree from the Columbia University School of Nursing in 1983.
She is a Chartered Financial Analyst.
Antiguos cargos conocidos de Maureen McEnroe.
| Empresas | Cargo | Fin |
|---|---|---|
Merlin Biomed Group Hedge Funds
 Merlin Biomed Group Hedge Funds Investment ManagersFinance Merlin BioMed invests globally in public and private healthcare companies. The firm's hedge funds and long-term appreciation fund seek maximum capital appreciation from broad-based, global investment in small-, mid- and large-cap public and private companies in the areas of biotechnology, pharmaceuticals, medical devices, healthcare services and research products/services. This investment objective is characterized by an intensive, research-oriented, fundamental, bottom-up approach with a focus on new product innovation as a driver of sales and earnings growth. For private equity, the MerlinNexus objective is to realize long-term capital appreciation from investments in late-stage private companies, PIPEs (private investments in public entities) and select open market transactions. The fund is invested in all segments of the healthcare industry, with an emphasis on product-driven life sciences companies developing breakthrough products that meet clinical needs and can positively alter disease course and associated costs. | Gestor de Cartera-Acciones | 30/11/2002 |
Merrill Lynch Capital Markets
 Merrill Lynch Capital Markets Investment Banks/BrokersFinance Security Brokers Dealers and Flotation Companies | Corporate Officer/Principal | 31/12/1994 |
Brenner Securities Corp
 Brenner Securities Corp Investment Banks/BrokersFinance Full service securities brokerage firm | Corporate Officer/Principal | - |
Merrill Lynch, Pierce, Fenner & Smith, Inc. /Old/
 Merrill Lynch, Pierce, Fenner & Smith, Inc. /Old/ Investment Banks/BrokersFinance Provides brokerage services | Corporate Officer/Principal | - |
Prudential Securities
 Prudential Securities Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | - |
Formación de Maureen McEnroe.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
98
Relaciones de 1er grado
8
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 8 |
|---|---|
Merrill Lynch, Pierce, Fenner & Smith, Inc. /Old/
Merrill Lynch, Pierce, Fenner & Smith, Inc. /Old/ Investment Banks/BrokersFinance Provides brokerage services | Finance |
Prudential Securities
Prudential Securities Investment Banks/BrokersFinance Provides brokerage services | Finance |
Merlin Biomed Group Hedge Funds
Merlin Biomed Group Hedge Funds Investment ManagersFinance Merlin BioMed invests globally in public and private healthcare companies. The firm's hedge funds and long-term appreciation fund seek maximum capital appreciation from broad-based, global investment in small-, mid- and large-cap public and private companies in the areas of biotechnology, pharmaceuticals, medical devices, healthcare services and research products/services. This investment objective is characterized by an intensive, research-oriented, fundamental, bottom-up approach with a focus on new product innovation as a driver of sales and earnings growth. For private equity, the MerlinNexus objective is to realize long-term capital appreciation from investments in late-stage private companies, PIPEs (private investments in public entities) and select open market transactions. The fund is invested in all segments of the healthcare industry, with an emphasis on product-driven life sciences companies developing breakthrough products that meet clinical needs and can positively alter disease course and associated costs. | Finance |
The Trustees of Columbia University in The City of New York
 The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Brenner Securities Corp
Brenner Securities Corp Investment Banks/BrokersFinance Full service securities brokerage firm | Finance |
New York University
 New York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merrill Lynch Capital Markets
Merrill Lynch Capital Markets Investment Banks/BrokersFinance Security Brokers Dealers and Flotation Companies | Finance |
Iguana Healthcare Management LLC
 Iguana Healthcare Management LLC Investment ManagersFinance Iguana Healthcare Management Healthcare’s investment objective is for its clients to maximum returns from investing long and short globally in public companies in the life sciences industry while actively managing both sector and global risk with an eye on capital preservation. The broad base of investment opportunities includes, but is not limited to companies focusing on biotechnology, branded pharmaceuticals, generic pharmaceutics, medical devices and medical supplies, healthcare service providers, and healthcare information technology. Iguana Healthcare clients’ portfolios are constructed using a multi-factorial approach with a focus on balancing risk and liquidity with expected returns on individual stocks and with their impact on upon overall portfolio concentration. Portfolios are constructed stock-by-stock and not sub-sector by sub-sector. | Finance |
- Bolsa de valores
- Insiders
- Maureen McEnroe
